Rapport Therapeutics (NASDAQ:RAPP) Given New $66.00 Price Target at HC Wainwright

Key Points

• HC Wainwright raised its price target for Rapport Therapeutics from $40 to $66 while maintaining a “Buy” rating, implying 38.22% upside from the previous close.
• Analyst sentiment is broadly positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $61.57, despite isolated “Sell” recommendations.
• Rapport reported quarterly EPS of -$1.19, missing consensus estimates of -$1.12; shares closed at $47.75, near their 52-week high of $49.50.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) had its target price boosted by equities research analysts at HC Wainwright from $40.00 to $66.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's price target would suggest a potential upside of 38.22% from the company's previous close. HC Wainwright also issued estimates for Rapport Therapeutics' Q3 2026 earnings at ($1.36) EPS, Q4 2026 earnings at ($1.54) EPS, FY2026 earnings at ($4.51) EPS, FY2027 earnings at ($6.80) EPS, FY2028 earnings at ($8.40) EPS, FY2029 earnings at ($8.08) EPS and FY2030 earnings at ($6.96) EPS.

Several other analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of Rapport Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rapport Therapeutics in a research note on Friday, July 17th. Citigroup reissued a "market outperform" rating on shares of Rapport Therapeutics in a research report on Tuesday, June 2nd. William Blair started coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 28th. They issued an "outperform" rating for the company. Finally, Truist Financial assumed coverage on shares of Rapport Therapeutics in a research note on Monday, May 18th. They set a "buy" rating and a $56.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $61.57.

Rapport Therapeutics Price Performance

Shares of NASDAQ:RAPP traded down $1.07 during midday trading on Wednesday, reaching $47.75. 125,066 shares of the company's stock were exchanged, compared to its average volume of 348,491. The stock has a market cap of $2.29 billion, a price-to-earnings ratio of -15.71 and a beta of 0.97. Rapport Therapeutics has a fifty-two week low of $13.86 and a fifty-two week high of $49.50. The firm's 50 day simple moving average is $40.25 and its two-hundred day simple moving average is $34.91.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.07). Equities research analysts predict that Rapport Therapeutics will post -4.09 earnings per share for the current fiscal year.

Insider Transactions at Rapport Therapeutics

In other Rapport Therapeutics news, major shareholder Rock Ventures V. L.P. Third sold 18,572 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $40.05, for a total transaction of $743,808.60. Following the sale, the insider owned 6,280,525 shares in the company, valued at approximately $251,535,026.25. This represents a 0.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $42.11, for a total transaction of $93,063.10. Following the sale, the chief executive officer owned 537,607 shares of the company's stock, valued at approximately $22,638,630.77. This trade represents a 0.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 12.48% of the company's stock.

Institutional Investors Weigh In On Rapport Therapeutics

Large investors have recently made changes to their positions in the business. KBC Group NV bought a new stake in Rapport Therapeutics in the first quarter valued at about $30,000. Meeder Asset Management Inc. bought a new stake in Rapport Therapeutics during the 4th quarter valued at $37,000. Russell Investments Group Ltd. acquired a new stake in Rapport Therapeutics in the third quarter worth about $43,000. State of Wyoming acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter worth approximately $65,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Rapport Therapeutics by 64.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company's stock valued at $70,000 after purchasing an additional 905 shares in the last quarter.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source